AnkeBio Rallies Nearly 20% in a Week After U.S. Medicare Reimbursement Milestone

Preface

AnkeBio (安克生醫, 4188-TW) advanced sharply during the week after its Anke Sleep Apnea Detector secured reimbursement for testing through U.S. Medicare at Stanford Sleep Medicine Center. The development offers a practical example of how the company’s technology can be incorporated into clinical workflows and supported through an existing medical reimbursement code. AnkeBio also reported ongoing efforts to expand its overseas presence, including completed device delivery and clinical deployment in Turkey, continued activity at its Dubai location, and discussions concerning cooperation in the United Kingdom. This article reviews the company’s share performance, the role of its sleep apnea screening product, and progress involving its thyroid assessment product and international partnerships. The central development is the connection between clinical adoption, reimbursement, and broader market access.

Lazy bag

AnkeBio gained 19.1% for the week, closing at 17.15 yuan on Thursday (22nd) after hitting the daily limit-up, and moved above all moving averages. Institutional investors recorded net buying for 3 consecutive trading days, totaling 227 lots for the week. The company said its Anke Sleep Apnea Detector received Medicare payment for testing at Stanford Sleep Medicine Center, where adoption has expanded from screening toward treatment assessment and referral. The product uses non-invasive ultrasound and AI to screen for obstructive sleep apnea (OSA) risk in 10 minutes. Overseas progress includes Turkey, Dubai, and United Kingdom discussions, while the thyroid product is used by more than 30 medical institutions across Taiwan. Reimbursement validation and clinical integration are key elements of the company’s growth story.

Main Body

AnkeBio’s shares recorded a notable weekly rise following a clinical and reimbursement milestone for its Anke Sleep Apnea Detector. The product secured payment for testing through U.S. Medicare at Stanford Sleep Medicine Center, a development that the company says supports its efforts to build a presence in the U.S. market. The news coincided with a weekly share-price gain of 19.1%, while investor attention also focused on the company’s overseas activity and other medical technology products.

During the week, AnkeBio shares rose 19.1%. On Thursday (22nd), the stock reached the daily limit-up and closed at 17.15 yuan, moving above all moving averages. The three major institutional investor groups were net buyers for 3 consecutive trading days. Their combined net purchases for the week totaled 227 lots. These figures describe the trading performance reported for the period; they do not, on their own, establish the reasons for the share-price movement or predict future performance.

The company’s sleep apnea product, Anke Sleep Apnea Detector, is designed to assess the risk of obstructive sleep apnea (OSA). It combines non-invasive ultrasound with AI analysis and can complete a risk-screening process in 10 minutes. The approach is intended to provide a screening option without an invasive procedure. In practice, however, a screening result is only one element of care: clinical teams may need to interpret the findings alongside other information and determine whether further evaluation, treatment assessment, or referral is appropriate.

Stanford Sleep Medicine Center has worked with AnkeBio since 2019. According to the company, the center has progressively incorporated the product into its clinical workflow. Its use has extended beyond screening to include treatment assessment and referral. This progression is significant because it suggests a broader role within patient-care processes than a stand-alone screening test. The reported adoption also provides a clinical setting in which the product’s workflow and practical application can be assessed.

A particularly important development is that testing fees were covered through U.S. Medicare by using an existing medical procedure code. This means the company did not describe the outcome as the creation of a new payment code; rather, the test received payment through an established code associated with medical services. Reimbursement can be an important consideration when healthcare providers evaluate whether to adopt a technology, since payment arrangements may affect the financial and administrative conditions for use. The Stanford case therefore gives AnkeBio a concrete example of how its product may be used within a U.S. clinical and reimbursement environment.

The milestone may help the company present its product to potential U.S. partners and healthcare providers, but it should be understood within its reported scope. The information concerns payment for testing at Stanford Sleep Medicine Center and does not establish that reimbursement is available at every U.S. institution or in every clinical setting. Adoption elsewhere may depend on provider decisions, applicable payment rules, workflow requirements, and evidence gathered through use. The reported achievement is best viewed as an important market-development example rather than a guarantee of broad or automatic coverage.

AnkeBio is also pursuing international expansion for the sleep apnea product. The company has completed device delivery and clinical deployment in Turkey. At its Dubai location, it continues to generate applications, while it is discussing potential cooperation in the United Kingdom. The company is advancing both equipment sales and software subscription services. These approaches represent distinct commercial elements: devices may support initial implementation, while software subscriptions may provide an ongoing service component. The company’s update describes progress and discussions, rather than confirming completed commercial agreements in every market.

The overseas activities indicate that AnkeBio is exploring more than one route to market. Clinical deployment can help establish familiarity with a product among healthcare users, while local partnerships may provide access to institutions and operational support. At the same time, each market has its own healthcare practices and purchasing arrangements. The company’s reported work in Turkey, Dubai, and the United Kingdom therefore reflects a developing international strategy, but the scale and timing of future adoption remain dependent on execution and local conditions.

Beyond sleep apnea screening, AnkeBio’s thyroid product, Anke Thyroid Detector, has been adopted by more than 30 medical institutions across Taiwan. The company expects to submit a temporary payment plan, known as HTR, to relevant experts in the fourth quarter. The plan is intended to support the next stage of collecting real-world data. Such data can offer information about how a product performs and is used in routine healthcare settings, complementing assessments conducted in more controlled environments. The update identifies a planned submission and future data-collection effort; it does not state that the plan has already been approved.

Internationally, AnkeBio is pursuing technical integration and cooperation discussions with medical imaging platforms CARPL, deepc, and SECTRA. The company hopes to use the platforms’ hospital networks to accelerate the overseas expansion of its products. Platform integration can potentially help connect a medical technology with existing institutional systems and users, although the commercial impact depends on the details and outcomes of the discussions. The company described these efforts as ongoing cooperation talks and technology integration work, not as finalized partnerships with confirmed sales results.

Taken together, the company’s update presents two related themes: clinical integration and market access. For Anke Sleep Apnea Detector, the Stanford experience combines product use in a clinical workflow with Medicare payment for testing under an existing code. For Anke Thyroid Detector, adoption across more than 30 medical institutions in Taiwan and a planned HTR submission point toward continued evidence gathering. Overseas deployments and platform discussions add further routes for potential expansion. These developments provide context for the stock’s weekly performance, while leaving important questions—such as the breadth of reimbursement, the pace of adoption, and the results of international discussions—to be answered over time.

Key Insights Table